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A B S T R A C T
Wnt signaling has been a topic of research for many years for its diverse and fundamental functions in phy-
siological (such as embryogenesis, organogenesis, proliferation, tissue repair and cellular differentiation) and
pathological (carcinogenesis, congenital/genetic diseases, and tissue degeneration) processes. Wnt signaling
pathway aberrations are associated with both solid tumors and hematological malignancies. Unregulated Wnt
signaling observed in malignancies may be due to a wide spectrum of abnormalities, from mutations in the genes
of key players to epigenetic modifications of Wnt antagonists. Of these, Wnt antagonists are gaining significant
attention for their potential of being targets for treatment and inhibition of Wnt signaling. In this review, we
discuss and summarize the significance of Wnt signaling antagonists in the pathogenesis and treatment of he-
matological malignancies.
1. Introduction
The first description of deregulated Wnt signaling in a hematolo-
gical malignancy was reported in chronic myeloid leukemia (CML) [1].
CML is a clonal hematopoietic stem cell (HSC) disease characterized
clinically by an increase in myeloid lineage cells at all stages of dif-
ferentiation. The translocation −t(9;22)(q34;q11)- leading to the for-
mation of the Philadelphia chromosome (derivative 22) is the hallmark
of CML. This translocation results in the fusion of the proto-oncogene
ABL located on the long arm of chromosome 9, with the BCR gene on
chromosome 22 [2]. The BCR-ABL oncoprotein possesses an un-
regulated increased tyrosine kinase activity that has been shown to
drive the disease in terms of cell proliferation and resistance to pro-
grammed cell death [3]. There are several signaling pathways that have
been determined to play a prominent role in CML progression. Among
them the Wnt signaling pathway stands out with its unique role in the
formation of a second leukemic stem cell population derived from
granulocyte-macrophage progenitors. The neoplastic transformation of
a HSC, results in the overproduction of granulocytes; thus forming the
initial BCR-ABL positive leukemic stem cell (LSC) pool [4]. In the
normal HSC, nuclear accumulation of β-catenin has been shown to be
the driving force of self-renewal; its nuclear accumulation is therefore
limited to HSCs in the bone marrow [5]. It is established that granu-
locyte-macrophage progenitors from advance stage CML patients dis-
play self-renewal capacity (a capability they normally do not possess),
as a result of an overly active β-catenin/canonical Wnt signaling
pathway, leading to two pools of Ph(+) cells with self-renewing ca-
pacity.
The importance of the Wnt signaling pathway in hematological
malignancies is not limited to CML. Over-expression and aberrant
regulation of Wnt signaling, mutations in downstream pathway mem-
bers and silencing of Wnt antagonists by epigenetic regulation have all
been reported in different hematological malignancies [6–8]. The epi-
genetic silencing of Wnt antagonists is of special interest and they are
considered promising targets which carry the potential to be exploited
in designing new agents and therapeutic strategies.
In this review, we focus on the role of Wnt antagonists in leukemia,
with a special focus on CML; and discuss potential therapeutic oppor-
tunities presented by Wnt antagonists in hematological malignancies.
1.1. The Wnt signaling pathway
Wnt signaling is involved in many biological processes, including
cell adhesion, migration, apoptosis, polarity, proliferation, develop-
ment and organogenesis [9]. Secreted Wnt proteins act as ligands for
the Frizzled (Fzd) receptor family and trigger paracrine/autocrine sig-
naling through the Fzd proteins in the cell [9,10]. The ligand-receptor
specificity between the 19 Wnt ligands and more than 15 receptors/co-
receptors leads to the activation of intracellular Wnt signaling that is
classified as canonical and non-canonical pathways; in which the
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canonical pathway is responsible for preventing the degradation of β-
catenin [11]. When Wnt signaling is not activated, β-catenin accumu-
lation is prevented by its degradation by a multiprotein complex that is
composed of Axin and adenomatous polyposis coli (APC) proteins (both
defined as tumor suppressors), the Ser/Thr kinases GSK-3 and CK1,
protein phosphatase 2A (PP2A), and the E3-ubiquitin ligase β-TrCP. A
β-TrCP recognition site is generated by this degradation complex
through the phosphorylation of β-catenin on a conserved Ser/Thr-rich
sequence near its amino terminus; thus marking it for degradation by
the proteasome [12].
Canonical Wnt signaling is triggered by the binding of the Wnt li-
gand to the Fzd receptor in the presence of the co-receptor LRP5 or 6
(Low-density lipoprotein receptor-related protein) which in turn
transfers the signal into the cell [5,9]. Receptor-ligand coupling results
in the phosphorylation of Dishevelled (Dvl) proteins. The resulting Dvl/
Fzd receptor complex stimulates the formation of LRP aggregates in the
cell membrane and CK1γ phosphorylation of the intracellular domains
of the LRP receptors. These signaling events lead to Axin being trapped
by the receptor complex. Phosphorylated Dvl disrupts the Axin-APC-
GSK3β degradation complex, inhibiting the phosphorylation of β-ca-
tenin and suppressing proteosomal degradation. As a result, β-catenin
levels rise in the cytoplasm and translocate to the nucleus. Nuclear β-
catenin interacts with members of the Tcf/Lef transcription factor fa-
mily and binds to co-activator proteins converting them into tran-
scriptional activators of Wnt target genes [13].
Non-canonical Wnt pathways are defined as pathways that do not
involve β-catenin stabilization. Presently eleven different non-canonical
Wnt pathway has been identified (eg Wnt/RAP1, Wnt/Ror2, Wnt/PKA,
Wnt/GSK3, Wnt/RYK, Wnt/mTOR ect.). Some of these pathways also
use/interact with Fzd transmembrane proteins as receptor. Non-cano-
nical pathways in which Fzd receptors are involved are divided into
Wnt/planar cell polarity (PCP) and Wnt/Ca2+ pathways [14].
In Wnt/Ca2+ signaling, intracellular calcium release is triggered by
the binding of the Wnt ligand to its Fzd receptor, followed by G protein
signaling leading to PKC-mediated cleavage of phosphatidolinoside to
diacylglycerol and inositol 1,4,5 triphosphate. Activation of secondary
messengers triggers intracellular calcium release resulting in calcium
dependent kinase activation such as CamKII and CaCN. These kinases
activate the expression of transcriptional co-activators such as NFAT
and NFkB [15]. This pathway is known to play an important role in
regulating cell adhesion, cell migration, embryonic development of
dorso-ventral patterns and development of the heart [16].
The Wnt/PCP pathway plays important roles in regulating mor-
phogenic polarization, cell fate, embryonic morphogenesis and cellular
mobility [16]. It’s activated by the binding of ligands that function in
non-canonical signaling such as Wnt5a, Wnt5b, Wnt11, to Fzd family
proteins or ROR2, ROR1 and Ryk receptors [17]. Similar to LRP5/6,
ROR1 and ROR2 are phosphorylated by GSK3β and interact with Dsh
proteins after Wnt5a binding. As a result a Fzd/ROR active receptor
complex is formed [15]. This complex activates Dvl which in turn
transduces the signal to small GTPases and JNK (C-Jun NH2-terminal
kinase) via R protein, G protein, RhoA, Rac and Cdc42 [18].
Recent studies have identified a new “alternative Wnt pathway” in
which β-catenin is replaced by YAP/TAZ proteins. YAP/TAZ proteins
are transcriptional regulators of the hippo pathway, the key regulator of
organ size and tissue homeostasis [19]. In the absence of Wnt ligands,
YAP/TAZ allows aggregation of β-TrCP and acts as a negative regulator
of the Wnt pathway. When Wnt signaling is activated, YAP/TAZ and β-
TrCP are removed from the degradation complex by Axin1. Free YAP/
TAZ on the contrary, acts as a positive transcriptional regulator of the
Wnt pathway [20]. Park et al. have shown YAP/TAZ accumulates in the
nucleus through Wnt5a/b and Wnt3a and transcriptionally regulates
the expression of various genes [19].
Recent and ongoing studies are constantly identifying new mole-
cules associated with Wnt signaling. Of these, newly identified Wnt
agonists, Norrin and R-Spondin are worth mentioning [21]. Norrin
binds directly to the Fzd4/LRP5 complex and activates signal trans-
duction. R-Spondin binds to G-protein-coupled receptors (Lgr4-6) and
inhibits the ubiquitination and degradation of Fzd proteins [22,23].
Both proteins are described as positive regulators of the Wnt pathway.
1.2. Wnt signaling in Hematological Malignancies
It is well established that the Wnt/β-catenin pathway controls the
proliferation, survival and differentiation of hematopoietic cells [24].
Continuous stimulation of Wnt signaling results in the neoplastic
transformation of myeloid and lymphoid lineages. Physiologically the
pathway is regulated stringently [25]. In healthy cells β-catenin levels
are tightly controlled by secreted and/or intracellular located inhibitory
proteins. Epigenetic abnormalities and silencing suppressors of the
pathway trigger the increase of β-catenin levels, leading to the un-
controlled activation of the Wnt signaling pathway [26,27].
Canonical Wnt signaling is significant for the maintenance and es-
tablishment of fetal HSCs [28]. Wnt signaling can directly promote HSC
self-renewal and has the ability to reconstitute the hematopoietic
system of lethally irradiated mice [29]. Wnt signal strength was shown
to regulate normal hematopoiesis [30]. Research over the past years has
led to our understanding that Wnt signaling is a critical regulator of
distinct aspects of self-renewal and differentiation in stem cells of the
hematopoietic system [28]. The differential expression of canonical
Wnt signaling was shown to have opposing effects on HSCs. Con-
stitutive activation of β-catenin has been demonstrated to induce HSC
re-population ability and inhibited differentiation [31]. On the other
hand non-canonical Wnt signaling also plays an important role in HSC
physiology. Non-canonical Wnt signaling maintains quiescent long-
term HSCs the bone marrow niche and has been shown to have a role in
the aging of HSCs [32,33].
Being a central element of HSC development and maintenance, it is
not surprising that the deregulation of this pathway plays a role in
leukemia development and progression. Clinical and experimental
studies have shown that Wnt signal transduction is impaired in hema-
tological malignancies. The most apparent result of deregulated Wnt
signaling is the increase of intracellular β-catenin levels. Sadras et al.
have shown that β-catenin expression is upregulated in primary AML
cells and is associated with enhanced clonogenic and self-renewal ca-
pacity [34]. The aberrant activation of Wnt/β-catenin has also been
implicated in the development and progression of acute lymphoblastic
leukemia (ALL). The expression levels of Wnt ligands, effects dose de-
pendent regulation of Wnt signaling in hematopoiesis [31]. Wnt ligands
WNT2B, WNT5A, WNT10B, WNT16B and Wnt receptors FZD7 and
FZD8 were reported to be overexpressed in B cell progenitor ALL cells
and primary B-ALL cells. LEF1 is also shown to be overexpressed in ALL,
CLL and malignant lymphoma [35].
Wnt signaling is known to prolong leukemic stem cell (LSC) sur-
vival. Similar to its effects on HSC’s, Wnt/β-catenin signaling is re-
quired for the self-renewal of LSCs [36]. Additionally canonical Wnt
signaling has anti-apoptotic effects in the LSCs of leukemia models
when challenged with anti-cancer drugs [6]. Wnt signaling especially
has a pivotal role in the different compartments of CML-LSC develop-
ment [37]. β-catenin overexpression is observed in the LSCs during the
accelerated stage of disease and blast crisis [1]; pointing to the cano-
nical Wnt pathway as a good therapeutic target in CML-LSCs.
Epigenetic dysregulation is another cause of the Wnt⁄β-catenin
pathway dysfunction in solid tumors and hematological malignancies
[38]. Promotor methylation of Wnt antagonists were detected in mul-
tiple types of hematological malignancies and correlated with poor
prognosis. The epigenetic silencing of one or multiple Wnt antagonists
results in the constitutive activation of the pathway. The presence of
chimeric oncogenes such as AML1/RUNX1, MLL/PTD, PML/RARα, has
been reported to correlate with the hyper-methylation and silencing of
Wnt inhibitors [35].
Although most research conducted on Wnt signaling in
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hematological malignancies focus on the Wnt/β-catenin pathway, in-
terest in non-canonical signaling is on the rise. Non-canonical pathways
have been reported to function as tumor suppressors in mouse myeloid
and lymphoid leukemia models [39]. Similar to the canonical Wnt
pathway, non-canonical signaling is involved in the self-renewal and
maintenance of HSCs. It has been shown that two player of non-cano-
nical signalling –Flamingo (Fmi) and Fzd 8- maintain quiescent long-
term HSCs [33]. Wnt5a signals through the non-canonical Wnt⁄Ca2+
pathway and has been shown to supress cyclin D1. Research on animal
models suggests it acts as tumor suppressor. WNT5a expression was
inhibited in ALL patients by promoter methylation, which correlated
with upregulation of cyclin D1 expression and poor prognosis[40].
Another study has shown that targeting the non-canonical Wnt⁄ Ca2+
pathway leads to impaired NFAT activity and decreased cytokine pro-
duction, increasing sensitivity to Bcr-Abl inhibition in a mouse model of
Bcr-Abl+ ALL [41].
Uncontrolled activation of the Wnt/PCP pathway leads to more
malignant phenotypes, disruption of tissue polarity, invasion, metas-
tases in human tumors [17]. Deregulated WNT/PCP signaling drives the
pathogenesis of chronic lymphocytic leukemia (CLL). Targeting casein
kinase (CK) 1δ/ε, a key component of this pathway has synergetic ef-
fects on therapeutic strategies based on inhibiting B-cell receptor (BCR)
signaling [42]. Furthermore The Wnt/PCP pathway co-receptor ROR1
was found to be expressed on the surface of CLL cells and not on mature
healthy B cells; thus presenting itself as a target for future therapeutic
strategies [43–45].
1.3. Wnt Inhibitors/Antagonists
Wnt antagonists are an additional Wnt signaling balancing me-
chanism, evolutionally gained in vertebrates. Wnt antagonists resemble
guards controlling Wnt signaling pathway activity. So far six family
members of intracellular and secreted Wnt signaling inhibitors:
Dickkopf proteins (Dkks), secreted Frizzled-related proteins (sFRPs),
Wnt-inhibitory factor 1 (WIF-1), Wise/SOST, Cerberus, insulin-like
growth-factor binding protein 4 (IGFBP-4); and four family members of
transmembrane proteins: Shisa, Wnt-activated inhibitory factor 1
(Waif1/5T4), adenomatosis polyposis coli down-regulated 1 (APCDD1),
and Tiki1 proteins, have all been defined as acting as Wnt antagonists
[46]. The common mode of action is to prevent binding of Wnt ligands
to their cell surface receptors, thereby inhibiting Wnt/receptor stabili-
zation and further pathway activation. Many studies have shown that
the downregulated expression of Wnt antagonists via epigenetic in-
activation plays a significant role in the etiopathogenesis of different
forms of cancer. Abnormal changes in expression levels of these an-
tagonists are reported to be related with decreased survival in several
hematological malignancies [35]. Though we know that Wnt antago-
nists play a significant role in the regulation of Wnt signaling; research
on the pathophysiological effects of their dysregulation in hematologic
malignancies is limited. Some Wnt antagonists interact directly with
Wnt proteins while others act on the Wnt receptor complex. Wnt an-
tagonists also have different transcript isoforms and not all of them act
like an antagonist, adding to the complexity of the regulation of Wnt
signaling. Below are the most studied Wnt antagonists; Dickkopf,
sFRP1, WIF1, SOST, WNT5a and their role in hematological malig-
nancies (Fig. 1).
1.3.1. Dickkopf (DKK)
Dickkopf proteins are secreted extracellular antagonists of Wnt
signaling. Four isoforms of the Dickkopf protein have been identified in
vertebrates: Dkk1, 2, 3, 4 [47]. Dkk1, 2 and Dkk4 can block canonical
Wnt signaling by inhibiting the function of the LRP5/6 coreceptors, but
they do not function in non-canonical Wnt pathways such Wnt/PCP and
Wnt/Ca2+ signaling [48]. Dkk1 is the most well-known and studied
protein isoform of Dkks. Dkk1 forms a complex with LRP5/6 and
Kremen (Krm), resulting in the endocytosis of the complex and
sequestration of LRP5/6 from the cell surface [49]. Recombinant Dkk1
protein has been used as an efficient Wnt/β-catenin pathway inhibitor,
in vitro settings [50]. In addition, Dkk1 was shown to inhibit pro-
liferation and induce apoptosis in human renal cell carcinoma [51].
Dkks have an affinity for Krm proteins [52], by which they can
induce the proteasomal degradation of β-catenin [53]. Interestingly
Dkk2 can function as a Wnt/LRP6 signaling agonist or antagonist and
both functions are mediated through Krm2. It must be noted that Dkk2
alone cannot activate the Wnt/β-catenin signaling and that the LRP6
levels modulate Dkk2-mediated activation of the Wnt pathway [54].
The effects of DKK3 on Wnt signaling are controversial and may differ
between tissue and tumor cell types. For example; DKK3 was reported
to selectively activate the c-Jun-NH2-kinase in human prostate cancer
cells, leading to the inhibition of the non-canonical Wnt pathway [48].
There are a couple of studies examining the role of the Wnt an-
tagonist Dkk proteins in leukemia. Staal et al. showed that DKK3 is
epigenetically downregulated by hyper methylation, resulting in an
over active Wnt signaling in the primary CLL and B-ALL cells [8]. It was
demonstrated that in addition to promoter hyper methylation, post-
translational mechanisms also regulates DKK3 expression in adult B-
ALL [48]. The relative expression of DKK3 was lower in bone marrow
cells of AML and ALL patients than in normal controls [55]. There is
evidence that miR-708 regulated the expression levels of Dkk3 and in
the presence of a miR-708 inhibitor Dkk3 expression levels increase,
independent of promoter demethylation. Restoration of Dkk3 leads to
the suppression of the Wnt/β-catenin signaling pathway and conse-
quently suppression of cell growth [48]. Hyper methylation of DKK1
has also been associated with the activation of the Wnt pathway and
poor prognosis in AML patients [8]. Dkk1 is overexpressed in multiple
myeloma (MM); thus termed as one of the pro-myeloma factors [56].
Tian et al. demonstrated that Dkk1 levels increase in MM patients [57]
and the neutralization of Dkk1 may have beneficial effects in the
treatment of MM [50]. Liang et al. reported that cordycepin –an ade-
nosine analogue- induces Dkk1 expression via autocrine and paracrine
pathways in leukemia and mesenchymal stromal/stem cells (MSCs).
Paracrine Dkk1 secreted from MSCs was shown to inhibit leukemia and
cancer cell proliferation [58].
Several studies aimed at determining whether exploiting Dkk-1
signaling may be effective in leukemia treatment. In one study the
addition of recombinant Dkk1 protein to CLL cells failed to inhibit Wnt
signaling [59]; implying that although actively downregulated, Dkk1
alone is not sufficient in suppressing Wnt signaling in chronic leukemia
such as CML and CLL.
1.3.2. Wnt Inhibitory Factor 1 (WIF1)
WIF1 is a Wnt binding protein that prevents Wnt ligands to bind
with their associated membrane Frizzled receptors. Structurally WIF1
contains a N-terminal secretion signal sequence, WIF domain (WD, 143
amino acid residues), five epidermal growth factor (EGF) –like domains
(each 31–33 residues), and a hydrophilic C-terminal. The human Wif1
protein has been shown to be able to bind eight different secreted Wnt
proteins through the WD: Wnt3a, Wnt4, Wnt5a, Wnt9a, Wnt11,
Wingless and Xenopus Wnt8 [60]. Wif proteins inhibit Wnt/β-catenin
signaling by sequestering Wnt ligands [61]. Unlike Dkk proteins, Wif1
inhibits both canonical and non-canonical pathways [62].
Wnt/β-catenin signaling is stringently regulated in normal tissues
where Wif1 is one of the players that modulate Wnt/β-catenin signaling
activity. Functional loss of Wif1 by promoter hyper-methylation leads
to the activation of Wnt signaling, resulting in uncontrolled and in-
creased cell proliferation in a variety of cancers, such as colorectal,
prostate, melanoma, lung, breast, esophagus, stomach and bladder
[63]. Overexpression of WIF1 has been reported to inhibit cell growth
in lung and bladder cancers in vitro; another example in which the
down regulation of a Wnt pathway antagonist is observed during car-
cinogenesis and when restored has the ability to inhibit growth of
cancer cells [60].
M. Pehlivan et al. Leukemia Research 69 (2018) 24–30
26
There is limited research on the role of Wif1 in leukomogenesis. The
first report of Wif1 epigenetic down regulation in a hematological
malignancy was observed in CLL patients. In this study Wif1 was shown
to be a negative regulator of activated Wnt signaling in CLL [64]. In
another study Ghasemi et al. reported that WIF1 and DKK1 hyper me-
thylation were observed in AML patients; the observed hyper methy-
lation was relatively much higher in undifferentiated phenotypic sub-
groups (AML M0) when compared to more differentiated ones (AML
M5). This study was compared to others where lower rates of methy-
lation were observed in AML patients; concluding that the observed
differences may be due to different patient selection and their ethnic
differences [65]. Regarding therapeutic interventions, Pehlivan et al.
showed that induced WIF1 expression will sensitize CML cells to tyr-
osine kinase inhibitors, again making Wnt signaling a promising target
in TKI resistant patients. The WIF1 gene was reported to be hyper-
methylated in CML cell lines [27]. However, to date there has been no
reports on the expression levels and regulatory effect of WIF1 in CML
patients.
1.3.3. sFRP (Secreted Frizzled Related Protein)
The sFRP family of Wnt antagonists is comprised of sFRP proteins
numbered 1 through 5 [66]. sFRPs regulate Wnt signaling by binding to
Wnt ligands through their CRD domains, similar to those found on FZD
receptors. sFRPs can interfere with Wnt signaling by forming non-
functional complexes with Fzds or by interacting with Wnt proteins to
prevent them from binding to their Fzd receptors [67,68].
The sFRP gene family is often the target of epigenetic silencing by
DNA methylation. Changes in the expression of sFRP genes have been
demonstrated in various cancers such as colorectal, bladder, prostate,
endometrium, lung, breast, mesothelioma and chronic lymphocytic
leukemia. These observations have led to the mutual understanding
that sFRPs function as tumor suppressors [69]. Unlike Dkks, which
specifically inhibit Wnt/β-catenin signaling, sFRPs can inhibit non-ca-
nonical Wnt/PCP signaling, as they bind to both types of Wnts [46].
Being natural inhibitors of both canonical and non-canonical Wnt
signaling, sFRPs play important roles in the differentiation of hemato-
poietic precursors and maintenance of stem cells in the hematopoietic
system. Transgenic mice lacking the sFRP1 gene, display niche-depen-
dent self-renewal defects in their HSC, including quiescence loss and
self-renewal impairment [6]. In hematopoietic malignancies, epigenetic
downregulation of sFRPs are believed to play a role in disease patho-
genesis [70]. Methylation rate of sFRP1 was reported to be 51% in ALL
[71] and 100% in CLL [72]. Other studies also reinforce these ob-
servations, reporting promoter methylation and down regulation of
sFRP1, 2, 4 and 5 in primary CLL cells [8].
In myeloid leukemia’s, Reins et al. reported promoter methylation
and reduced expression levels of the sFRP1 gene 121 patients with
AML, ALL and MDS (myelodysplastic syndrome) at different risk groups
[73]. Aberrant methylation of sFRP genes varies in all Fab-AML sub-
groups. Epigenetic silencing of sFRP 1, 3, 4 leading to Wnt pathway
activation in AML [8]; where the highest incidence was observed in the
M4 and M1 FAB subgroups [74]. sFRP 1, 2, 4 and 5 promoter regions
were shown to be methylated in different AML cell lines and hyper-
methylation of at least one sFRP gene was reported to occurred in over
50% of AML patients. Guo et al. reported that AML patients in which
the sFRP1 promoter region was hypermethylated, had high incidence of
N/K-Ras mutations. They argued that hypermethylation of sFRPs
should be considered as an independent prognostic biomarker among
both cytogenetically normal AML patients and non-M3 AML patients
[7]. Uhm et al. determined that sFRP1 gene promoter methylation in
AML patients was significantly higher when compared to CML patients.
They reported methylation of the sFRP1 promoter region in 15 of the 23
AML patients (65.2%), compared to only 2 of the 21 CML patients
(9.5%) studied [75].
We have previously reported that albeit the observed infrequency in
chronic phase CML, when present sFRP1 promoter methylation corre-
lated with primary cytogenetic resistance to imatinib mesylate [76].
We’ve also shown that the sFRP1 gene is hyper methylated in CML cell
lines. Forced sFRP1 expression in CML cell lines will sensitize cells to
tyrosine kinase inhibitors. When sFRP1 and WIF1 are forced to re-ex-
pressed, they increase the apoptotic susceptibility of the cells in re-
sponse to tyrosine kinase inhibitors [27].
1.3.4. SOST
Sclerostin is the SOST gene product. It is expressed in several tissues
including bone, liver cartilage, kidney, heart, lung, pancreas and ske-
letal muscle. Its function has been mostly studied in bone tissue. Bone
tissue undergoes constant remodeling orchestrated mainly by three cell
Fig. 1. Regulation of Wnt signalling by an-
tagonists. Canonical Wnt/β-catenin pathway: In
the presence of Wnt antagonists (OFF state)
Wnt/receptor interactions are interrupted and
β-catenin is rapidly degraded via ubiquination
at the proteosome by the formation of the de-
struction complex (APC, Axin, GSK3β). In the
absence Wnt antagonists (ON state) Wnts form
a complex with the Frizzled receptor and cor-
eceptors LRP5/LRP6, resulting in the inhibition
of the destruction complex. This inhibition
leads to β-catenin accumulation in the cyto-
plasm, followed by its translocation to the nu-
cleus where it forms a complex with TCF/LEF
transcription factors and initiates transcription
of Wnt target genes. Non-canonical Wnt/Ca2+
pathway: Interaction of Wnt ligands with Fzd
receptors can lead to a release of intracellular
Ca2+. Intracellular calcium subsequently acti-
vates CAMKII and PKC in cells. Non-canonical
Wnt/PCP pathway: Wnts bind to transmem-
brane receptors ROR2 to activate planar cell
polarity. ROR2 activation leads to the activa-
tion of small GTPases, Rho and Rac; which in
turn activates JNK. The signaling cascade re-
sults in activation-specific gene transcription
through modulation of the AP-1 protein com-
plex.
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types: osteoclasts (bone resorbing cells), osteoblasts (responsible for the
bone synthesis and mineralization) and osteocytes. In bone, sclerostin is
primarily secreted by osteocytes; but osteoblasts and osteoclasts also
express SOST at low levels [77]. Sclerostin was originally defined as a
non-canonical bone morphogenetic protein (BMP) antagonist [78]. It
has been classified as a Wnt antagonist due to its inhibitory effect on
Wnt signaling. Circulating sclerostin binds to the LRP5/6 proteins
through the PE domain and inhibits the formation of the LRP5/6-friz-
zled receptor complex; leading to phosphorylation and subsequent de-
gradation of β-catenin and Wnt pathway inhibition [46,77,79]. Sup-
pression of the Wnt pathway by sclerostatin leads to an decrease in
bone development [80]. Due to this effect a human monoclonal scler-
ostin antibody which inhibits the binding of sclerostin to LRP5/6 has
been evaluated as part of a randomized, double-blind placebo con-
trolled phase I trial; and has shown promising results with increases in
bone mass density [81]. Similar antibodies have been developed and
phase II trials are underway. Nevertheless enhanced Wnt signaling has
been linked to different malignancies therefore the long-term safety
results of these therapeutic interventions are awaited.
There are only a limited number of papers of any role SOST may
have in cancer. Research in this area is focused on bone tumors and
skeletal sarcomas [82,83]. In the context of hematological malig-
nancies, sclerostin antibodies were reported to suppress tumor growth
in MM patients [84]. There are no reports on the role of SOST in leu-
komogenesis.
1.3.5. Wnt5A
The Wnt5a ligand is also a natural antagonist of Wnt signaling [8].
It has a role in both canonical and non-canonical Wnt pathways. Wnt5a
activates Wnt/PCP pathway signaling via activating small Rho-GTPases
[85]. On the other hand, Wnt5a has the ability to inhibit Wnt3a de-
pendent LRP6 phosphorylation and β-catenin accumulation in vitro by
competing with Wnt3a to bind to the Frizzled 2 receptor [86]. Evidence
indicates that Wnt5a exhibits dual effects on carcinogenesis depending
on context and tissue specificity. While favorable outcomes have been
reported in different tumors with high Wnt5a expression [87]; there are
also reports showing that over-expression of Wnt5a leads to a more
aggressive phenotype [88,89]. One explanation to this observed dis-
crepancy may be the involvement of different isoforms [90]. Never-
theless Wnt5a is emerging as an important player in cancer progression,
exerting both oncogenic and tumor suppressive effects [86].
There are fewer studies on the role of Wnt5A in leukemia; but as in
solid tumors, both oncogenic and tumor suppressive effects are ob-
served. One study reported epigenetic changes of Wnt antagonists in
acute leukemia and has shown that in most cases the Wnt5a promoter is
methylated [55]. Hatırnaz et al. showed that Wnt5a hyper methylation
has a direct effect on mRNA expression levels and Wnt5a acts as a
tumor suppressor in ALL patients [91]. It was also reported to act as
tumor suppressor in AML patients where the epigenetic inhibition of
Wnt5a leads to upregulation of Cyclin D1 expression and a poor prog-
nosis [92]. Exogenous Wnt5a expression enhances proliferation and
migration of CLL cells[93]. On the other hand in CLL, Wnt-5a functions
as an important regulator of ROR1 activity. Also autocrine Wnt5a was
shown to induce irregular motility and chemotaxis in primary CLL cells
[94]. Additionally, one report has shown that over expressing Wnt5a
increases the effects of imatinib in CML cells through the JNK/β-ca-
tenin/Survivin and γ-catenin/β-catenin/Survivin pathways [95].
1.4. Therapeutic potential of Wnt antagonists in Leukemia
Research has revealed Wnt pathways are central to the malignant
phenotype of many tumors. Thus many therapeutical approaches and
agents have been developed –some currently in clinical trails- that
specifically target one or more of the many players [96]. Re-expressing
epigenetically inhibited Wnt antagonists is also among therapeutical
strategies to be considered. Non-specific epigenetic modulation by
using histon deacetylase and DNA methylase inhibitors is currently part
of cancer therapy, including hematological malignancies. These agents
lead to the re-expression of Wnt antagonisits as well as other silenced
tumor suppressors. Specific targeting of antagonists is more challen-
ging; hence epigenetic modulation of a specific promotor/s is techni-
cally much more difficult. In this context replacement approaches ra-
ther than epigenetic modulation are favored. sFRP1 has been used in
the form of a recombinant therapeutic protein attached to gold nano-
particles that allowed release of sFRP1 outside the cells, resulting in the
inhibition of the malignant phenotype [97]. Advancements in nano-
medicine, where nanocarriers are taking center stage may lead to the
replacement of specific molecules –such as Wnt antogonists- in targeted
tissues. Viral vectors have also been used to deliver Wnt antagonists.
The intratumoral injection of an adenovirus vector carrying the Dkk-3
gene was reported to suppresses tumors in mesothelioma, prostate,
breast and testicular cancers [98]. Recombinant Dkk1 protein has been
used as a canonical Wnt signalling inhibitor, in-vitro settings [50]. In
addition, an adenosine analogue was shown to induce Dkk1 expression
through autocrine and paracrine pathways in leukemia and mesench-
ymal stromal/stem cells (MSCs). MSCs that secrete Dkk1 was shown to
inhibit proliferation in leukemia and cancer cells [58]. A few studies
have examined the utility of short peptides. SFRP1 or SFRP1-derived
peptides were shown to delay xenograft tumor formation in nude mice.
Likewise, the injection of full-length SFRP1 protein in xenografted
mammary tumors were shown to reduce tumor growth. Full-length
WNT5A both normal mammary cells and breast cancer cells invitro and
daily injections of a WNT5A-derived peptide reduced the number of
metastases in mice allografted with breast cancer cells [99]. SOST is a
exception among Wnt antagonists in that its inhibition –not activation-
benefits clinical outcomes in cancer. its exerts its inhibitory effect on
Wnt signaling binding to LRP5/6 proteins and inhibiting the formation
of the LRP5/6-frizzled receptor complex. Yet it is classified as a It has
been classified as a bone morphogenetic protein (BMP) antagonist with
roles in bone development [78]. Suppression of the Wnt pathway by
sclerostatin leads to an decrease in bone development [80]. SOST an-
tibodies prevented bone loss and reduced osteolytic bone lesions in
multiple myeloma [100]. A human monoclonal sclerostin antibody
which inhibits the binding of sclerostin to LRP5/6 is currently eval-
uated for clinical use in phase I and II trails [81].
On-going and future advances in gene therapy, microRNA delivery/
efficiency, CRISPR/Cas technologies are all promising approaches to
utilize therapeutic strategies to modulate Wnt antagonists in clinical
setting and their use in hematological malignancies.
1.5. Conclusion
Although we’ve come a long way in treating leukemia’s, research
efforts are being focused on developing newer and better regimens. The
Wnt signaling pathway is a crucial regulator of hematopoiesis and its
dysfunction has been implicated in the development of leukemia’s. In
recent years, research has shown that epigenetic silencing of Wnt an-
tagonists contributes to the abnormal activation of canonical Wnt sig-
naling. Wnt signaling pathway antagonists plays multiple roles in
human hematopoiesis. However, their precise roles and the causal
mechanisms in leukemia have not been clearly elucidated. Fully un-
derstanding the function of these epigenetically silenced regulators
enriches our repertoire of possible targets for therapy. Activated Wnt-
signaling may be a key molecular event, which is able to circumvent
classical therapeutical approaches. Wnt antagonists may carry the po-
tential to be exploited in designing new agents and strategies for the
different forms of leukemia; while Wnt signaling may be a target, in
therapy resistance disease.
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